<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="690">
  <stage>Registered</stage>
  <submitdate>13/09/2005</submitdate>
  <approvaldate>29/09/2005</approvaldate>
  <actrnumber>ACTRN12605000550606</actrnumber>
  <trial_identification>
    <studytitle>Evaluation of new drug treatments including artemisinin combination therapy for uncomplicated malaria in children in Papua New Guinea</studytitle>
    <scientifictitle>Evaluation of new drug treatments including artemisinin combination therapy for uncomplicated malaria in children in Papua New Guinea</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Malaria</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Chloroquine/sulfadoxine/pyrimethamine 
Dihydroartemisinin-piperaquine
Artesunate-piperaquine
Chloroquine
These drug regimes will be given by mouth in conventional doses over up to three days as treatment for malaria.</interventions>
    <comparator />
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>28-day cure rate as defined by the World Health Organisation</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Parasite clearance time</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Fever clearance time</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Children with a history of fever and a blood film positive for either P. falciparum or P. vivax will be eligible provided that: i) they have no features of severe malaria,34 ii) there is no history of prior antimalarial drug use (quinine or artemisinin drugs within 7 days, or a 4-aminoquinoline, pyrimethamine and/or sulphonamide within 28 days), iii) there is no clinical evidence of another infection as a cause of fever, and iv) the childs parents or relatives give informed consent.</inclusivecriteria>
    <inclusiveminage>4</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>10</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>A sequentially numbered sealed opaque envelope will contain each child's assigned treatment code</concealment>
    <sequence>Computer-generated randomisation</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/04/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>600</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Western Australia</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>Papua New Guinea Insitute of Medical Research</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Papua New Guinea</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>We aim to assess whether new combination therapies for malaria, based on artemisinin drugs and a chloroquine-like drug piperaquine, will be effective in children with malaria in Papua New Guinea</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Timothy Davis</name>
      <address>School of Medicine and Pharmacology
University of Western Australia
Fremantle Hospital
PO Box 480
Fremantle WA 6959</address>
      <phone>+61 8 94313229</phone>
      <fax>+61 8 94312977</fax>
      <email>tdavis@cyllene.uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Timothy Davis</name>
      <address>School of Medicine and Pharmacology
University of Western Australia
Fremantle Hospital
PO Box 480
Fremantle WA 6959</address>
      <phone>+61 8 94313229</phone>
      <fax>+61 8 94312977</fax>
      <email>tdavis@cyllene.uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>